Photocure Investor Hub
A commercial-stage company focused on bladder cancer
Hexvix®/Cysview® is a product for the detection of bladder cancer:
- Established position as an innovation leader in the large and underserved bladder cancer treatment market.
- Treatment guidelines and reimbursement supports market penetration.
- In excess of USD 40M in global market sales.
- Specialist salesforce established in the U.S. and Europe with additional potential value in other territories through our partners; Asieris MediTech Co., Ltd. (China), Endotherapeutics Group (Australia/New Zealand), Genotests (Chile) and IGL Medical (Israel).
- Large untapped potential for Hexvix®/Cysview® in existing and new market segments/territories.
- Opportunities following the FDA approval of Cysview® for use with flexible cystoscope.
- Exploring expansion of bladder cancer portfolio to leverage commercial infrastructure.
Society of Urologic Oncology 2023 Annual Meeting (SUO)28 Nov 2023 - 1 Dec 2023https://suonet.org/meetings/upcoming-meetings.aspx
Nordic- American Healthcare Conference in New York6 Dec 2023 - 7 Dec 2023
SEB Healthcare Seminar 2023 in Stockholm21 Nov 2023 - 23 Nov 2023
Analyst coverage Photocure ASA is followed by the analysts listed below. Please note that any opinions, estimates or forecasts regarding Photocure ASA's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Photocure ASA or its management. Photocure ASA does not by its reference below or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
ABG Sundal Collier
Tel: +46 733 26 37 69
Tel: +46 8 701 1995
Norne Securities AS
Tel: +47 21 95 37 49